ALTERNATE NAMES

Prenatal Onset Arthrogryposis Multiplex Congenital (SMA0); Werdnig-Hoffman Disease-Infantile Muscular Atrophy (SMA1)

DESCRIPTION

Spinal muscular atrophy (SMA) of all types belongs to a group of hereditary diseases that cause weakness and wasting of the voluntary muscles in the arms and legs of infants and children.

The disorders are caused by an abnormal or missing gene known as the survival motor neuron gene (SMN1), which is responsible for the production of a protein essential to motor neurons. Without this protein, lower motor neurons in the spinal cord degenerate and die. The type of SMA is determined by the age of onset and the severity of symptoms. Type 0 (SMA0) is prenatal. Type 1 (SMA1) (also known as Werdnig-Hoffman disease or infantile-onset SMA) is evident at birth or within the first few months.

Symptoms include floppy limbs and trunk, feeble movements of the arms and legs, swallowing difficulties, a weak sucking reflex, and impaired breathing. Legs tend to be more impaired than arms.

DIAGNOSTIC TESTING, PHYSICAL FINDINGS, AND ICD-9-CM/ICD-10-CM CODING

Diagnostic testing: The clinical evaluation includes a history and physical examination. Abnormalities may be detected during the pregnancy, especially with onset of fetal movements or may reveal another affected family member. The history should define the onset of the disease and its progression.

Physical findings: Physical symptoms may include:

• •

  Weakness;

• •

  Hypotonia;

• •

  Absent reflexes;

• •

  Muscle twitching and contractures;

• •

  Muscle atrophy;

• •

  Labored breathing with use of accessory muscles; and

• •

  Malnutrition.

Molecular testing of the SMN1 gene is needed for confirmation of diagnosis. Carrier status must be defined before prenatal diagnosis is attempted.

ICD-9: 335.1

ICD-10:G12

PROGRESSION

The prognosis is poor for infants with SMA0 and SMA1. SMA0 infants never achieve any motor milestones and usually die between 2 and 6 months of age. SMA1 children fare only slightly better in that they may achieve sitting with support only and survive to 2 years or less without respiratory assistance. SMA1 children may survive longer if offered non-invasive respiratory support (NIPPV or tracheotomy).

TREATMENT

There is no cure for SMA. There is no treatment for the progressive weakness caused by the disease. Treatment consists of managing the symptoms and preventing complications. Children with SMA0 or SMA1 require little, if any, involvement of an orthopedist due to their short life span. Supportive care is important. When nutrition/feeding become concerns, tube feeding via nasogastric tube or gastrostomy may be offered. Attention must be paid to the respiratory system, because affected children have difficulty clearing secretions. Respiratory complications are common.

SUGGESTED PROGRAMMATIC ASSESSMENT*

Suggested MER for Evaluation: The diagnosis is confirmed by molecular genetic testing of the SMN1 gene. Homozygous deletion of exon 7 of the SMN1 gene is seen in 95-98% of the cases while 2-5% of the cases will have this deletion in one chromosome and an intragenic mutation of the SMN1 gene in the other chromosome.

Suggested Listings for Evaluation:

DETERMINATION

REMARKS

Meets

110.08

111.22

Genetically confirmed SMA0 or SMA1.

Equals

111.22

Pending genetic confirmation but with a clinical diagnosis of SMA0 or SMA1.